Internal medicine

Hazard ratio

Androgen

Prostate cancer

Cancer

Urology

Oncology

Prostate

Confidence interval

Proportional hazards model

Radiation therapy

Hormone

Medicine

Advances in Radiation Oncology

Outcomes of stereotactic body radiation therapy (SBRT) with respect to androgen receptor signaling inhibitors (ARSI) have not been characterized for oligometastatic prostate cancer. We sought to characterize prostate specific antigen (PSA) response and progression-free survival (PFS) after SBRT among men who have progressed on ARSI therapy in the oligometastatic castration-resistant setting.

Evaluating the Role of Stereotactic Body Radiation Therapy With Respect to Androgen Receptor Signaling Inhibitors for Oligometastatic Prostate Cancer